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Abstract The yeast two-hybrid system and in vitro binding 
assay were carried out to characterize the interaction between 
PKN and a small GTP-binding protein, RhoA. It was revealed 
that the region corresponding to the amino acid residues 33-111 
in the amino-terminal region of PKN was sufficient o confer the 
ability to associate with RhoA. Each synthetic peptide fragment 
corresponding to the amino acid residues 74-93 and 94-113 of 
PKN inhibited the interaction between PKN and RhoA in the in 
vitro binding assay, suggesting that this region is important in the 
association with RhoA. The endogenous and the GAP-stimulated 
GTPase activity of RhoA was inhibited by the interaction with 
PKN, suggesting the presence of a regulatory mechanism that 
sustains the GTP-bound active form of RhoA. 
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1. Introduction 
PKN is a serine/threonine protein kinase with the catalytic 
domain highly homologous to that of protein kinase C, and 
its kinase activity is enhanced by unsaturated fatty acids such 
as arachidonic acid [1-3]. The N-terminal regulatory region of 
PKN contains repeats of a leucine zipper-like motif, suggest- 
ing protein-protein association through hydrophobic interac- 
tion [4], and a basic region located immediately N-terminal to 
the first leucine zipper-like motif, which are conserved 
through evolution in vertebrates [5]. We have recently re- 
ported that RhoA, a small GTP-binding protein implicated 
in multiple cell functions, specifically binds to the N-terminal 
regulatory region of PKN and activates PKN in a GTP-de- 
pendent manner, indicating that PKN functions as one of the 
target proteins of RhoA [6,7]. The precise binding region of 
PKN for RhoA and the effect of PKN on the GTPase activity 
of RhoA, however, are not known. In this study, we used the 
yeast two-hybrid system and in vitro binding assay to deter- 
mine the essential region in the N-terminal regulatory region 
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of PKN for binding with RhoA, and demonstrated that PKN 
inhibited the endogenous and the GAP-stimulated GTPase 
activity of RhoA. 
2. Materials and methods 
2.1. Materials and chemicals 
[~/-32p]GTP (1.11 TBq/mmol) was purchased from DuPont-New 
England Nuclear. Glutathione Sepharose 4B was purchased from 
Pharmacia Biotech Inc. Nitrocellulose filters (BA-85, 0.45 gm pore 
size) were obtained from Schleicher&SchueU. Synthetic peptide frag- 
ments for potential RhoA binding region of PKN were synthesized 
with an automated peptide synthesizer (Applied Biosystems, model 
431). All other chemicals were from commercial sources. 
2.2. Two-hybrid system 
The scheme of the fusion constructs for the truncated PKN cDNA 
used in this study is shown in Fig. 1B. The cDNA fragments encoding 
various lengths of human PKN were inserted into the vector 
pBTMll6 in frame with the upstream LexA DNA-binding domain 
sequences or the vector pVP16 in frame with the upstream VP16 
transcription activation domain sequences. The cDNA fragments en- 
coding human RhoA, RhoA v~la and RhoA al~z7, were obtained by 
digesting pGEX-RhoA, pGEX-RhoA wua, and pGEX-RhoA ~aaa7 
[7], respectively, then cloned into pBTM116 and pVP16. The cDNA 
fragment for human RhoA lacking the C-terminal lipid modification 
site (amino acid residues 190-193), which was designated RhoA 
CLVL-, was prepared by PCR and ligated into pBTMll6 and 
pVP16. 
The expression plasmids were transfected into yeast L40 cells and 
plated on semi-solid media lacking tryptophan and leucine. Interac- 
tion was examined using a filter lift assay for the [3-galactosidase 
activity as described previously [8]. 
2,3. Preparation of recombinant prote&s and in vitro binding assay 
[aSS]Methionine-labeled in vitro translation product corresponding 
to amino acid residues 1-474 of human PKN was prepared as de- 
scribed previously [9]. Expression vector for the N-terminal region of 
human PKN fused to GST was made by subcloning the cDNA frag- 
ment encoding amino acid residues 1-540 of human PKN into pGEX 
vector (Pharmacia Biotech Inc.). GST fusion proteins were expressed 
in E. coli and affinity-purified on glutathione-Sepharose columns as 
described previously [7]. PKN (amino acid residues 7-155) fused to 
MBP was prepared as described previously [7]. 50 nM of the guanine 
nucleotide bound form of RhoA fused to GST was incubated with 1.5 
lal of in vitro translated PKN in a total volume of 200 Ixl of binding 
buffer (20 mM Tris/HC1 at pH 7.5, 1 mM EDTA, 0.5 mM DTr, 5 
mM MgC12 and 1 I.tg/ml leupeptin) for 60 rain at 4°C. Then 40 ~tl of 
glutathione-Sepharose beads preincubated in binding buffer contain- 
ing 10 mglml E. coli extracts to block non-specific binding [10], was 
added and rotated for 30 min at 4°C. Unbound proteins were re- 
moved by four washes with binding buffer containing 0.2% Nonidet 
P-40 and 50 mM NaC1, and by two washes with binding buffer. 
Specifically bound proteins were eluted with binding buffer containing 
10 mM reduced glutathione, subjected to SDS-PAGE, and to auto- 
radiography as described previously [9]. Experiments with synthetic 
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peptides were performed using the various concentrations of peptide 
in 200 lal of the binding mixture. 
2.4. GTPase assay 
The assay for endogenous GTPase activity was carried out as fol- 
lows: 2 ~M of purified RhoA fused to GST was incubated with 5 ~tM 
of [y-a~P]GTP (1.11 TBq/mmol) in 50 mM Tris/HC1 at pH 7.5, 10 mM 
EDTA, 1 mM MgC12, 50 mM NaC1, 1 mM DTT, 0.3% CHAPS for 
10 min at 30°C. The exchange reaction was stopped by placing the 
reaction mixture on ice, followed by addition of MgC12 to a final 
concentration of 10 raM. The [y-a2P]GTP-loaded RhoA fused to 
GST or RhoA v~]14 fused to GST (0.2 IxM) was incubated at 30°C 
either with or without PKN (amino acid residues 1-540) fused to 
GST in 60 pJ of hydrolysis buffer (50 mM Tris/HC1 at pH 7.5, 5 
mM MgC12, 1 mM DTT, 1 mM GTP and 0.1 mg/ml bovine serum 
albumin). The reaction was stopped by the addition of about 2 ml of 
ice-cold 20 mM Tris/HCl at pH 7.5 containing 100 mM NaC1 and 25 
mM MgC12, followed by rapid filtration on a nitrocellulose filter. The 
filter was washed three times with the same ice-cold buffer. The radio- 
activity collected on the filter was determined. 
The GAP-stimulated GTPase activity of RhoA was assayed by 
measuring the decreased radioactivity of the [y-s2p]GTP-bound form 
of RhoA fused to GST for 2 min at 25°C in the presence of 50 nM of 
p122 Rho GAP fused to GST [11] and the various concentration of
A 
LexA fusion / VP16 fusion 
PKNl-(vectoronly) 
PKN/RhoA 
PKN t RhoA""' 
PKN/RhoA =~7 
PKN/RhoACLVL 
PKN/RhoA~"CLVL • 
PKN/RhoA"'TCLVL • 
LexA fusion / VP16 fusion 
- (vector only) / PKN 
RhoA / PKN 
RhoA~"/PKN 
RhoA'='/PKN 
RhoA CLVL/PKN 
RhoA =' CLVL/PKN 
RhoA '=7 CLVL / PKN 
B 
~-Galactosidase activity 
+-t"  
+++ 
+++ 
=~"~ Catalytic domain mum 
PKN ES IISI[-i, _ Ilmmmlllm  
Basic region 
3 
m 
31135 
1 540 
- I ] 
511 94~ 
Fig. 1. Interaction of PKN with RhoA in the two-hybrid system. 
Yeast IA0 cells were cotransfected with expression vectors encoding 
various LexA DNA binding domain and VP16 transcription activa- 
tion domain fusion proteins. Interaction was examined using a filter 
lift assay for 13-galactosidase activity. (A) Specificity of the interac- 
tion of the N-terminal regulatory region of PKN with wild type or 
mutants of RhoA. 'PKN' indicates the N-terminal regulatory region 
of PKN (amino acid residues 1-540). 'CLVL' indicates the deletion 
mutant which lacks the C-terminal lipid modification site. (B) Iden- 
tification of the RhoA binding region of PKN. The schematic whole 
structure of PKN is represented at the top of the figure, and the de- 
letion mutants are aligned below. 'LZ' indicates leucine zipper-like 
motif. '+++' and '++' indicate the development of strong color 
within 20 and 60 min from initiation of the assay, respectively. ' - '  
indicates no development of color within 24 h. The results shown 
are representative of three independent experiments. 
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Fig. 2. In vitro interaction of the N-terminal regulatory region of 
PKN with RhoA. In vitro translated PKN and GST fusion proteins 
were incubated with glutathione-Sepharose beads, washed, and sub- 
jected to SDS-PAGE and to autoradiography, as described in sec- 
tion 2. (A) Specific interaction between the N-terminal regulatory 
region of PKN and the GTPyS-bound form of RhoA. (B) Effects of 
the various synthetic peptide fragments on the interaction between 
PKN and RhoA. The GTPTS-bound form of RhoA fused to GST 
was incubated with in vitro translated PKN in the presence of the 
indicated concentration of the peptides for the potential RhoA bind- 
ing region of PKN. The results shown are representative of three in- 
dependent experiments. 
PKN (amino acid residues 7-155) fused to MBP [7] in 100 I11 of 
reaction mixture (20 mM Tris/HC1 at pH 7.5, 10 mM EDTA, 1 mM 
DTT, 10 mM MgC12, 1 mM GTP, 0.075% CHAPS, 0.25 mM L-C~- 
dimyristoylphosphatidylcholine, 100 nM [7-32p]GTP-bound form of 
RhoA fused to GST) [11]. 
3. Results and discussions 
We have recently shown that PKN forms a complex with 
the GTP-bound form of RhoA but not with the GDP-bound 
form [6,7]. To characterize the association between PKN and 
RhoA further, the yeast two-hybrid system was carried out. 
The N-terminal regulatory region of human PKN (amino acid 
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Fig. 3. Effects of PKN on the GTPase activity of RhoA. (A) Effects of added protein on the endogenous GTPase activity of RhoA. 200 nM 
of the [7-32p]GTP-bound form of RhoA (o, ©, ×) or RhoA van4 (zx) were incubated with (O) or without (©) 150 nM of the N-terminal region 
of PKN fused to GST or incubated with GST alone (×) for the indicated times at 30°C, and the residual bound radioactivity was determined 
by a filter binding assay. The remaining [7-32P]GTP bound to each protein was expressed asa percentage of that measured at 0 min of incuba- 
tion. (B) Dose-dependent ffect of PKN. 200 nM of the [y-32p]GTP-bound form of RhoA fused to GST was incubated for 10 min with various 
concentrations of the N-terminal region of PKN fused to GST. The residual bound radioactivity of RhoA fused to GST preloaded with [7- 
32p]GTP was measured as described in the legend to (A). (C) Effects of PKN on GAP-stimulated GTPase activity of RhoA. 100 nM of the [7- 
32p]GTP-bound form of RhoA fused to GST was incubated for 2 min at 25°C in the presence of 50 nM of p122 Rho GAP fused to GST and 
various concentrations of the N-terminal region of PKN fused to MBP. The residual bound radioactivity of RhoA fused to GST preloaded 
with [7-32p]GTP was measured as described in the legend to (A). The results hown are representative of three independent experiments. 
residues 1-540) fused to the LexA DNA binding domain was 
coexpressed with human RhoA or RhoA mutants fused to the 
VP16 activation domain in yeast strain L40. As shown in Fig. 
1A, the I]-galactosidase activity was obviously induced in the 
transformants expressing PKN and RhoA v°a14, a GTPase-de- 
fective mutant [12], whereas it was detected in neither the 
transformants expressing PKN and wild-type RhoA nor the 
transformants expressing PKN and RhoA "a"zT, an effector do- 
main mutant [7,13]. The Rho family members have a CAAX 
motif (C, cysteine; A, aliphatic acid; X, any amino acid) in 
their C-terminal region, and undergo post-translational mod- 
ifications including eranylgeranylation, proteolysis, and car- 
boxyl-methylation [14,15]. To prevent association of RhoA 
fusion proteins with membranes, RhoA mutants designated 
CLVL-, which lack the C-terminal lipid modification site, 
were tested by the two-hybrid system. PKN interacted with 
RhoA CLVL- and with RhoA vaIl4 CLVL-, though not with 
RhoA al~z7 CLVL-. Similar results were obtained from the 
combination of RhoA fused to LexA and PKN fused to 
VP16 (Fig. IA). Thus, the specific interaction between acti- 
vated RhoA and PKN was supported by the two-hybrid sys- 
tem, and these results uggest that the CAAX motif of RhoA 
is not required for the interaction with PKN. 
To identify the binding region of PKN for RhoA, the var- 
ious expression plasmids for the truncated PKN were trans- 
fected with RhoA va~14 CLVL- into yeast cells. As shown in 
Fig. 1B, RhoA w114 CLVL- interacted with the region corre- 
sponding to amino acid residues 33-111 of PKN in the two- 
hybrid system. This result is consistent with recent observa- 
tions [6,7]. Since this region of PKN contains the first leucine 
zipper-like motif [1,2], this motif may have some role in the 
interaction between PKN and RhoA. 
Next, we measured the binding between in vitro translated 
PKN and the GTPTS-bound form of RhoA fused to GST in 
the presence of synthetic peptides corresponding to the var- 
ious N-terminal regions of PKN. As shown in Fig. 2A, in the 
absence of peptide, in vitro translated PKN bound specifically 
to the GTPyS-bound form of RhoA fused to GST. Each syn- 
thetic peptide fragment corresponding to amino acid residues 
74-93 and 94-113 of PKN inhibited the binding of PKN to 
the GTP?S-bound form of RhoA in a concentration-depend- 
ent manner (Fig. 2B). These results suggest hat the region 
corresponding to amino acid residues 74-113 of PKN is crit- 
ical for this interaction. 
Several protein kinases, such as the activated Cdc42Hs-as- 
sociated kinase p120 AcK and the p21 (Cdc42/Rac)-activated 
kinase p65 PAK, which bind to the active form of small 
GTPases, have been found to inhibit the endogenous and 
the GAP-stimulated GTPase activity of these small GTP bind- 
ing proteins [16,17]. These effects of target protein kinases on 
GTPase activity are important for signal duration. To deter- 
mine whether the GTPase activity of RhoA could be affected 
by the binding to PKN, the residual bound radioactivity of 
RhoA fused to GST or RhoA v~114 fused to GST preloaded 
with [y-32p]GTP was measured in the presence or absence of 
PKN. As shown in Fig. 3A, the half-life of GTP bound to 
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RhoA fused to GST was 12 min, while that of RhoA va114 
fused to GST was increased to greater than 100 min. The 
addition of the N-terminal region of PKN (amino acid resi- 
dues 1-540) fused to GST increased the half-life of GTP 
bound to RhoA fused to GST from 12 to more than 20 
min at 30°C, but the addition of GST alone did not affect 
the GTP hydrolysis rate. These results indicate that the N- 
terminal region of PKN has an activity to inhibit the endo- 
genous GTPase activity of RhoA. This inhibition was depend- 
ent on the concentration of PKN (Fig. 3B). As shown in Fig. 
3C, the N-terminal region of PKN fused to MBP (amino acids 
7-155) inhibited p122 Rho GAP-stimulated GTPase activity 
of RhoA fused to GST in a concentration-dependent manner, 
suggesting that the N-terminal region of PKN inhibits the 
interaction of GAP with RhoA. Rhotekin, a novel putative 
target for Rho, bearing a homologous equence to the N- 
terminal region of PKN, inhibits both the endogenous and 
the GAP-stimulated GTPase activity of RhoA [18], suggesting 
this conserved Rho binding motif is implicated in the regula- 
tion of the GTPase activity. 
Recently, the GTP-bound form of RhoA was found to bind 
to and stimulate Rho kinase/ROKa nd pl60 a°cu, which are 
members of the serine/threonine protein kinases [19-21]. In 
Saccharomyces cerevisiae, the GTP-bound form of Rholp, a 
yeast homologue of mammalian RhoA, interacts with Pkclp, 
leading to the activation of the MAP kinase cascade [22]. 
However, there is no homology in primary amino acid se- 
quences for the RhoA binding region between these protein 
kinases and PKN. ROKct was reported to have no effect on 
the GTPase activity of RhoA [20]. Taken together, there 
might be various modes of interaction of RhoA with the tar- 
get. It is important to identify physiological targets for PKN 
and to examine the activation mechanism of PKN. 
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